key: cord-0835348-hadhcgjd
authors: Yu Phuan, Crystal Zhen; Ci-En Choi, Ellie; Oon, Hazel H.
title: Temporary exacerbation of pre-existing psoriasis and eczema in the context of COVID-19 mRNA booster vaccination: a case report and review of the literature.
date: 2021-12-18
journal: JAAD Int
DOI: 10.1016/j.jdin.2021.11.004
sha: e0d62d51dbf692e30d2c9a13bde89828c0ae5ab5
doc_id: 835348
cord_uid: hadhcgjd

nan

In addition, FDA has also authorized the use of heterologous booster dose for these three vaccines, 11 at least six months after completion of the Pfizer-BioNTech and Moderna primary series and two 12 months after completion of single-dose Janssen primary regimen. A critical appraisal of the initial FDA 13 guidelines approving use of COVID-19 vaccination in immunocompromised persons has supported 14 booster doses for immunocompromised dermatology patients, such as those on prednisolone ≥20 mg 15 daily, biologics or methotrexate. 2 In view of increasing booster dose approvals in many countries 16 worldwide, it is important for dermatologists to be familiar with possible cutaneous adverse events 17 with booster doses. We report two cases of exacerbation of underlying dermatosis after booster doses. 18

The first patient is a 71-year-old male with a history of localised eczema, who presented with new 20 onset vesicular and discoid lesions within 24 hours of the third Pfizer-BioNTech vaccination. He had a 21 similar but milder reaction after his second vaccination dose. Physical examination revealed 22 eczematous and weepy discoid plaques on the trunk, limbs ( Figure 1A ) and chest ( Figure 1B) and 23 multiple deep-seated vesicles on the palms ( Figure 1C) . He was treated with topical steroids, 24 antihistamines, oral antibiotics and prednisolone. 25

One week after her third dose of Pfizer-BioNTech vaccination, she developed a guttate flare with an 28 active body surface area of 5% ( Figure 1D ). Cyclosporine was increased to 75mg daily with the addition 29 of topical steroids. Limitations of this study include the inability to establish causality. However, our cases show temporal 43 association without other qualifying triggers and satisfy most criteria described in causality 44 assessment of an adverse event following immunization. 5 Physicians are encouraged to monitor for 45 possible cutaneous vaccine related complications (Table 1) 

COVID-19) Update: FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19

Dermatology Patients on Biologics and Certain Other Systemic Therapies Should Receive a 'Booster' mRNA COVID-19 Vaccine Dose: A Critical Appraisal of Recent FDA and ACIP Recommendations

Pfizer and BioNTech initiate rolling submission of supplemental biologics license applications to U.S. FDA for booster dose of Comirnaty in individuals 16 and older

Safety Monitoring of an Additional Dose of COVID-19 Vaccine -United States

Causality Assessment of an Adverse Event following Immunization (AEFI): User Manual for the Revised WHO Classification